Treatment-resistant depression in adolescents: review and updates on clinical management
Open accessThe DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Abstract
Treatment-resistant depression (TRD) in adolescents is prevalent and impairing. We here review the definition, prevalence, clinical significance, risk factors, and management of TRD in adolescents. Risk factors associated with TRD include characteristics of depression (severity, level of hopelessness, and suicidal ideation), psychiatric and medical comorbidities, environmental factors (family conflict, maternal depression, and history of abuse), and pharmacokinetics and other biomarkers. Management options include review of the adequacy of the initial treatment, re-assessment for the above-noted factors that might predispose to treatment resistance, switching antidepressants, and augmentation with medication or psychotherapy. Other modalities, such as electroconvulsive therapy, vagal nerve stimulation, and repetitive transcranial magnetic stimulation, are also reviewed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bridge, J. A., Iyengar, S., Salary, C. B., Barbe, R. P., Birmaher, B., Pincus, H. A., Ren, L., & Brent, D. A. (2007) · JAMA · doi:10.1001/jama.297.15.1683 · Cited by 1,086
Self-citationMajor depressive disorder in older adolescents
Lewinsohn, P. M., Rohde, P., & Seeley, J. R. (1998) · Clinical Psychology Review · doi:10.1016/s0272-7358(98)00010-5 · Cited by 1,078 · cited 1×
“Most common are diagnoses of Attention Deficit Hyperactivity Disorder (ADHD), dysthymic disorder, anxiety disorders, and substance abuse.[1,11,12] Comorbidities with dysthymic disorder is most highly correlated with poor prognosis and response to SSRI medication[13,14] and the presence of ADHD moderated treatment resp…”
BackgroundBirmaher, B., & Brent, D. (2007) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/chi.0b013e318145ae1c · Cited by 1,056 · cited 6×
“[3] Adequate treatment is defined as 8–12 weeks of optimal pharmacological treatment that consists of at least 4 weeks of fluoxetine (20 mg) or its equivalent and a dose increase if no response is obtained for an additional 4 weeks.[1,4] Adequate psychotherapy course is defined as the use of CBT or IPT for 8–16 sessio…”
BackgroundMethodInfluentialSelf-citationCorrell, C. U. (2009) · JAMA · doi:10.1001/jama.2009.1549 · Cited by 1,050 · cited 1×
“[57] Disadvantages of the use of atypical antipsychotics in this population include risk of weight gain, obesity, and metabolic syndrome.[58] Augmentation of SSRI with either sustained-release bupropion or buspirone appears to be useful in resistant depression in adults as demonstrated in STAR D.”
BackgroundMedication Augmentation after the Failure of SSRIs for Depression
Trivedi, M. H., Fava, M., Wisniewski, S. R., Thase, M. E., Quitkin, F., Warden, D., Ritz, L., Nierenberg, A. A., Lebowitz, B. D., Biggs, M. M., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa052964 · Cited by 1,002 · cited 1×
“Here, augmentation with sustained-release bupropion had certain advantages, including a greater reduction in the number and severity of symptoms and fewer side effects and adverse events.[59] Such augmentation strategies have not been systematically studied in adolescents although open-label studies have suggested the…”
BackgroundManber, R., Edinger, J. D., Gress, J. L., Pedro-Salcedo, M. G. S., Kuo, T. F., & Kalista, T. (2008) · Sleep · doi:10.1093/sleep/31.4.489 · Cited by 868
Wilkinson, P., Kelvin, R., Roberts, C., Dubicka, B., & Goodyer, I. (2011) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2010.10050718 · Cited by 645 · cited 1×
“[29] These findings were similar to the ADAPT trial, in which ideation, family difficulties, and nonsuicidal self-injury were predictors of suicidal events.[80] In TORDIA, in addition, venlafaxine treatment was associated with a higher rate of self-harm adverse events in those with higher suicidal ideation and adjunct…”
ResultNemeroff, C. B., Mayberg, H. S., Krahl, S. E., McNamara, J., Frazer, A., Henry, T. R., George, M. S., Charney, D. S., & Brannan, S. K. (2006) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301082 · Cited by 496 · cited 1×
“Initially used for the treatment of refractory epilepsy in both children and adults, VNS has shown to improve mood in patients receiving this treatment, which lead to it being approved by the FDA in 2005 for use in TRD only in adults.[66] The mechanism of action of VNS has not been well defined and no studies have bee…”
Stanley, B., Brown, G., Brent, D. A., Wells, K., Poling, K., Curry, J., Kennard, B. D., Wagner, A., Cwik, M. F., Klomek, A. B., et al. (2009) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/chi.0b013e3181b5dbfe · Cited by 423 · cited 1×
“[29] Reduction in suicidal events may be achieved by accelerating initial treatment response, addressing family conflict and drug and alcohol use, and psychosocial interventions such as developing a good safety plan and emotion regulation skills.[81]”
BackgroundSelf-citation
Cited by
Treatment-resistant depression: therapeutic trends, challenges, and future directions
Al-harbi (2012) · Patient Preference and Adherence · doi:10.2147/ppa.s29716 · Cited by 796
“In a recent review, risk factors for treatment-resistant depression in adolescents were identified to be the severity of depression, level of hopelessness and suicidal ideation, psychiatric and medical comorbidities, environmental factors such as family conflict, maternal depression, and history of physical and sexual…”
Abnormal Amygdala Resting-State Functional Connectivity in Adolescent Depression
Cullen, K. R., Westlund, M. K., Klimes-Dougan, B., Mueller, B. A., Houri, A., Eberly, L. E., & Lim, K. O. (2014) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2014.1087 · Cited by 324
Wang, P., Wang, X., Wu, Y., Xie, X., Wang, X., Zhao, F., Ouyang, M., & Lei, L. (2018) · Personality and Individual Differences · doi:10.1016/j.paid.2018.02.008 · Cited by 221
Antidepressants and Suicidality
Brent, D. A. (2016) · Psychiatric Clinics of North America · doi:10.1016/j.psc.2016.04.002 · Cited by 119
Self-citationInternet Addiction and Depression in Chinese Adolescents: A Moderated Mediation Model
Chi, X., Liu, X., Guo, T., Wu, M., & Chen, X. (2019) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2019.00816 · Cited by 70
Metadata
- Authors
- Maalouf, F. T., Atwi, M., & Brent, D. A.
- Venue
- Depression and Anxiety
- Publisher
- Hindawi Limited
- Published
- 2011-09-02
- Volume
- 28
- Issue
- 11
- Pages
- 946-954
- ISSN
- 1091-4269 (ISSN-L)
- OpenAlex
- W2001307591
- Cited by
- 99
- References
- 20
- FWCI
- 4.38
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Treatment-resistant depression in adolescents: review and updates on clinical management. https://app.cochat.ai/papers/10.1002/da.20884
- The paper
- Maalouf, F. T., Atwi, M., & Brent, D. A. (2011). Treatment-resistant depression in adolescents: review and updates on clinical management. Depression and Anxiety. https://doi.org/10.1002/da.20884
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.